Tarsus Pharmaceuticals, Inc.
TARS
$59.00
-$0.83-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.97M | -8.37M | -12.59M | -20.34M | -25.12M |
| Total Depreciation and Amortization | 437.00K | 443.00K | 460.00K | 453.00K | 460.00K |
| Total Amortization of Deferred Charges | 159.00K | 156.00K | 152.00K | 146.00K | 139.00K |
| Total Other Non-Cash Items | 11.20M | 13.53M | 10.90M | 6.71M | 5.78M |
| Change in Net Operating Assets | -29.48M | 13.58M | 19.33M | -16.36M | -1.91M |
| Cash from Operations | -24.65M | 19.33M | 18.26M | -29.39M | -20.65M |
| Capital Expenditure | -5.82M | -6.36M | -1.91M | -1.00M | -590.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -52.74M | 55.63M | -2.83M | -50.70M | -34.35M |
| Cash from Investing | -58.56M | 49.27M | -4.74M | -51.70M | -34.94M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.20M | 2.31M | 2.56M | 1.95M | 136.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.20M | 2.31M | 2.56M | 1.95M | 136.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -82.01M | 70.92M | 16.08M | -79.14M | 80.97M |